I-HDS and TCI-BSRF (Biostatistics Shared Resource Facility) invites you to join its Biostatistics Seminar Workshop being held, Thursday, Nov. 8th at 2:00pm in room 9-101 in the Hess (CSM) Building, 9th Floor. Our featured guest will be Rong Chen, PhD, VP of R&D, Sema4 and Asst. Prof., Genetics and Genomics, ISMMS.
Talk Title: "Advancing precision medicine through data science"
Large scale implementation of next generation sequencing based clinical genetic testing and electronic medical records in the health care system provides an unprecedented opportunity for precision medicine. We have been developing clinical software to automate literature evidence collection, automate genetic variant pathogenicity assessment according to clinical guidelines, and integrate various types of molecular measurements for comprehensive clinical reports. We have further used natural language processing (NLP) and expert curation to develop tools to abstract comprehensive clinical data from physician notes, from diagnosis, pathology, clinical outcome, to co-morbidity automatically. Integrating both genetic and longitudinal clinical data into a structured database, we are now able to use real-world patient data to match patients to the right treatment towards precision medicine.
Rong Chen is VP of R&D Bioinformatics at Sema4 Genomics, a next generation health information company, and Assistant Professor at Icahn School of Medicine at Mount Sinai. Dr. Chen is an expert on translational bioinformatics and has published 100 papers in journals such as Nature Biotechnology, Lancet, and Science Translational Medicine. He has developed numerous databases and software to integrate genetic and clinical data to drive clinical diagnosis, precision medicine, and drug discovery, including knowledge bases for cancer and inherited diseases, VIAS for genetic variant annotation, VISta for clinical variant pathogenicity assessment, ClinLabGeneticist for clinical exome sequencing, and ZDOCK for protein-protein docking.
Dr. Chen has led the resilience project to identify genetic ‘superheroes’ in more than 589,000 individuals, a personalized cancer therapy project, and real-world cancer patient clinical data for precision medicine. He has illustrated the genetic landscapes of parathyroid carcinoma and Cushing’s disease, identified potential therapeutic targets for cardiovascular diseases, and diagnostic biomarkers for organ transplant rejection. He published the first Clinical Assessment of Human Genome and is a leader in the development of the personal genome report.
Dr. Chen has built a startup company called Personalis and served in the advisor boards for several genome informatics companies, including Bina Technologies (bought by Roche) and Tute Genomics.
Thursday, November 8 at 2:00pm to 3:00pm
Hess Building, 9-101 1470 Madison Avenue, New York, NY 10029